Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services, as well as nutrition and health products for immune, gut, reproductive, and sleep health management. It also provides information software and supporting hardware products. In addition, the company offers blood gas and chemistry analyzers, fluorescence immunoassay analyzers, molecular diagnosis kit, coagulation analysis machine, and automated glycohemoglobin detection machine. Wuhan Easy Diagnosis Biomedicine Co.,Ltd. was founded in 2008 and is based in Wuhan, China.
Research context
Wuhan Easy Diagnosis Biomedicine Co.,Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Wuhan Easy Diagnosis Biomedicine Co.,Ltd is currently in a long term uptrend where the price is trading 15.7% above its 200 day moving average.
From a valuation standpoint, the stock is 30.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.7.
Wuhan Easy Diagnosis Biomedicine Co.,Ltd's total revenue rose by 637.9% to $280M since the same quarter in the previous year.
Its net income has increased by 3353.4% to $156M since the same quarter in the previous year.
Finally, its free cash flow grew by 279.5% to $30M since the same quarter in the previous year.
Based on the above factors, Wuhan Easy Diagnosis Biomedicine Co.,Ltd gets an overall score of 5/5.